🚀 VC round data is live in beta, check it out!
OnKure Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for OnKure Therapeutics and similar public comparables like BGM Group, Arovella Therapeutics, Cantourage Group, Acrivon Therapeutics and more.
OnKure Therapeutics Overview
About OnKure Therapeutics
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research.
Founded
2011
HQ
Employees
46
Website
Sectors
Financials (LTM)
EV
$3M
OnKure Therapeutics Financials
OnKure Therapeutics reported last 12-month revenue of $183K.
In the same LTM period, OnKure Therapeutics generated $183K in gross profit and had net loss of ($60M).
Revenue (LTM)
OnKure Therapeutics P&L
In the most recent fiscal year, OnKure Therapeutics reported revenue of — and EBITDA of ($59M).
OnKure Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $183K | XXX | — | XXX | XXX | XXX |
| Gross Profit | $183K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($59M) | XXX | XXX | XXX |
| EBIT Margin | (34692%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($60M) | XXX | ($60M) | XXX | XXX | XXX |
| Net Margin | (32814%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
OnKure Therapeutics Stock Performance
OnKure Therapeutics has current market cap of $61M, and enterprise value of $3M.
Market Cap Evolution
OnKure Therapeutics' stock price is $4.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3M | $61M | -2.3% | XXX | XXX | XXX | $-4.35 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOnKure Therapeutics Valuation Multiples
OnKure Therapeutics trades at 16.2x EV/Revenue multiple, and (0.1x) EV/EBITDA.
EV / Revenue (LTM)
OnKure Therapeutics Financial Valuation Multiples
As of April 11, 2026, OnKure Therapeutics has market cap of $61M and EV of $3M.
Equity research analysts estimate OnKure Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OnKure Therapeutics has a P/E ratio of (1.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $61M | XXX | $61M | XXX | XXX | XXX |
| EV (current) | $3M | XXX | $3M | XXX | XXX | XXX |
| EV/Revenue | 16.2x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.0x) | XXX | (0.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 16.2x | XXX | — | XXX | XXX | XXX |
| P/E | (1.0x) | XXX | (1.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified OnKure Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
OnKure Therapeutics Margins & Growth Rates
OnKure Therapeutics' revenue in the last 12 month grew by 265%.
OnKure Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.4M for the same period.
OnKure Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 265% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 13% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8040% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 26672% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
OnKure Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BGM Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cantourage Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Acrivon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Entera Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OnKure Therapeutics M&A Activity
OnKure Therapeutics acquired XXX companies to date.
Last acquisition by OnKure Therapeutics was on XXXXXXXX, XXXXX. OnKure Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by OnKure Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOnKure Therapeutics Investment Activity
OnKure Therapeutics invested in XXX companies to date.
OnKure Therapeutics made its latest investment on XXXXXXXX, XXXXX. OnKure Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by OnKure Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout OnKure Therapeutics
| When was OnKure Therapeutics founded? | OnKure Therapeutics was founded in 2011. |
| Where is OnKure Therapeutics headquartered? | OnKure Therapeutics is headquartered in United States. |
| How many employees does OnKure Therapeutics have? | As of today, OnKure Therapeutics has over 46 employees. |
| Who is the CEO of OnKure Therapeutics? | OnKure Therapeutics' CEO is Nicholas A. Saccomano. |
| Is OnKure Therapeutics publicly listed? | Yes, OnKure Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of OnKure Therapeutics? | OnKure Therapeutics trades under OKUR ticker. |
| When did OnKure Therapeutics go public? | OnKure Therapeutics went public in 2024. |
| Who are competitors of OnKure Therapeutics? | OnKure Therapeutics main competitors are BGM Group, Arovella Therapeutics, Cantourage Group, Acrivon Therapeutics. |
| What is the current market cap of OnKure Therapeutics? | OnKure Therapeutics' current market cap is $61M. |
| What is the current revenue of OnKure Therapeutics? | OnKure Therapeutics' last 12 months revenue is $183K. |
| What is the current revenue growth of OnKure Therapeutics? | OnKure Therapeutics revenue growth (NTM/LTM) is 265%. |
| What is the current EV/Revenue multiple of OnKure Therapeutics? | Current revenue multiple of OnKure Therapeutics is 16.2x. |
| Is OnKure Therapeutics profitable? | No, OnKure Therapeutics is not profitable. |
| What is the current net income of OnKure Therapeutics? | OnKure Therapeutics' last 12 months net income is ($60M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.